<DOC>
	<DOCNO>NCT00351650</DOCNO>
	<brief_summary>This study test dihydrotetrabenazine , 11C-DTBZ , radioactive tracer , image agent positron emission tomography ( PET ) . That tracer may ability noninvasively measure beta cell , , -cell mass ( BCM ) human . For researcher hop develop new treatment diabetes mellitus , method measure BCM important . In study , researcher determine patient Type 1 diabetes mellitus , almost BCM , much less pancreatic uptake tracer patient without diabetes . Patients age 18 older may eligible study . Three group study : Participants Type 1 diabetes , without diabetes , successfully treat transplant pancreas pancreas kidney The study involve three set test do outpatient admit hospital . Patients undergo medical history procedure include collection blood ( 4 teaspoon ) , pregnancy test woman childbearing age , magnetic resonance imaging ( MRI ) scan , PET scan , test involve arginine glucose . Arginine substance stimulate insulin release -cells . During procedure , two intravenous ( IV ) line place arm , one administer arginine draw blood ( eight sample 10 minute ) . For glucose test , patient drink solution dextrose , sugar , blood sample take 2 hour IV line . Some patient experience nausea drinking solution . Within 48 hour either test , patient place PET scan machine give injection radioactive material IV line . Blood sample one-half teaspoon drawn procedure start every 10 second first 2 minute several interval , 60 minute . Finally , patient also MRI scan , 30 60 minute long , abdomen . This test within two week PET scan . MRI use strong magnetic field radio wave obtain image body organ tissue . During scan , patient ask lie still table slide tunnel scanner . They give earplug , machine noisy . Patients metal within body compatible MRI machine withdrawn study .</brief_summary>
	<brief_title>Assessment Beta Cell Mass Type 1 Diabetes With 11C-Dihydrotetrabenazine PET Scan</brief_title>
	<detailed_description>Diabetes metabolic disorder pancreatic insulin produce B-cells ( locate cell cluster call islet Langerhans ) long produce sufficient insulin maintain individual 's blood sugar concentration within normal range . Insufficient B-cell function cause autoimmune kill B-cells type 1 diabetes mellitus ( T1DM ) , poorly understood mechanism type 2 diabetes mellitus ( T2DM ) . Regardless underlying cause , development new diabetes treatment limit current inability objectively measure B-cell mass . We propose test previously use clinical radioligand , dihydrotetrabenazine ( DTBZ ) , Positron Emission Tomography ( PET ) image agent ability non-invasively measure B-cell mass human . We study 30 patient , 10 T1DM , 10 normal glucose homeostasis , 5 history T1DM , successfully restore glucose homeostasis follow whole pancreas transplantation . Prior PET scan , patient undergo metabolic test characterize glucose homeostasis insulin produce capacity . The pancreas initially identify patient high-resolution magnetic resonance imaging ( MRI ) . Then , use anatomical landmark identify MRI , subject undergo DTBZ-PET imaging . We predict radioactivity signal pancreas DTBZ-PET image significantly different control subject T1DM subject . Further , predict DTBZ-PET image obtain individual function pancreas allograft ( patient two pancreases- native pancreas pancreas allograft ) reveal signal intensity two gland correlate closely gland 's insulin produce capacity . Should study suggest DTBZ merit beta cell image agent , expand study include patient T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>INCLUSION CRITERIA Patients T1DM inclusion criterion : 1 . Age great 18 2 . History consistent T1DM 1. nonobese ( BMI le 35 kg/m ( 2 ) ) , 2. normal insulin sensitivity ( judge insulin requirement less equal 0.8 unit/kg/day ) . 3 . Low CPeptide ( less equal 0.6 ng/ml ) Pancreas Transplant Patient inclusion criterion : 1 . Age great 18 2 . History consistent T1DM ( ) PRIOR pancreas transplant . 3 . Normal pancreas allograft function least precede 1 year . 4 . No acute rejection episode within past year . Control Patient inclusion criterion : 1 . Age great 18 2 . No history diabetes . 3 . Fasting blood glucose le 100 mg/dl . 4 . Normal oral glucose tolerance . 5 . BMI le 35 kg/m ( 2 ) Exclusion criterion : 1 . Liver dysfunction determine history , physical examination , standard liver function test ( abnormal value AST , ALT , Total/Direct Bilirubin , Alkaline Phosphatase ) 2 . Coagulopathy 3 . Pregnancy 4 . Current breast feeding 5 . Use MAO inhibitor Levodopa 6 . Patients contraindication MRI scanning .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 6, 2008</verification_date>
	<keyword>Imaging</keyword>
	<keyword>Type 1 Diabetes Mellitus ( T1DM )</keyword>
	<keyword>Islet</keyword>
	<keyword>B Cell Mass</keyword>
	<keyword>Pet Scan</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>T1DM</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>